Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

NCT05048056 is registered in ClinicalTrials.gov with Akesobio Australia Pty Ltd as lead sponsor.

NCT NCT05048056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05048056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
Akesobio Australia Pty Ltd
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2021
Completion date
May 17, 2023
Enrollment
79 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis